Interim report
Page 1
Q3Q3 Third quarter 2026 results
Page 2
Table of Contents Gentian Diagnostics.......................................................................................................................................................................................................... 3 Third quarter 2026 highlights ................................................................................................................................................................................. 3 CEO Commentary – Recor d sales and significantly more new development projects initiated...............................................4 About Gentian Diagnostics ...................................................................................................................................................................................... 5 Illustration of product categories ......................................................................................................................................................................... 5 Gentian’s strategy for long-term growth and value creation.................................................................................................................... 5 Operational summary....................................................................................................................................................................................................... 7 Sales................................................................................................................................................................................................................................... 7 Market development GCAL® .................................................................................................................................................................................... 9 Pipeline development ............................................................................................................................................................................................. 10 Long-term outlook .......................................................................................................................................................................................................... 12 Financial performance.................................................................................................................................................................................................. 14 Revenue, geographic split and product split.................................................................................................................................................14 Statement of Profit and Loss – Gentian Diagnostics Gr oup (unaudited) ........................................................................................17 Notes........................................................................................................................................................................................................................................ 21 Note 1. General information ................................................................................................................................................................................ 21 Note 2. Accounting principles ............................................................................................................................................................................ 21 Note 3. Sales revenue............................................................................................................................................................................................. 22 Note 4. Cost of goods sold................................................................................................................................................................................... 22 Note 5. Other income.............................................................................................................................................................................................. 22 Note 6. Public grants .............................................................................................................................................................................................. 22 Note 7. Expenses by nature ................................................................................................................................................................................. 23 Note 8. Research and Development (R&D) expenses ..............................................................................................................................23 Note 9. Intangible assets...................................................................................................................................................................................... 23 Note 10. Interest bearing debt............................................................................................................................................................................ 24 Note 11. Share capital and number of shares ............................................................................................................................................24 Note 12. Earnings per share ................................................................................................................................................................................ 25 Note 13. Share-based compensation .............................................................................................................................................................25 Note 14. Tax................................................................................................................................................................................................................ 26 Alternative performance measures...................................................................................................................................................................27 Q3Q3 | Table of Contents Third quarter 2026 results 2
Page 3
Gentian Diagnostics Third quarter 2026 highlights RecorRecord salesd sales 51.151.1 NOK millNOK mill EBIEBITDTDAA 13.613.6 NOK millNOK mill GrGross Maross Margingin 61%61% FFrrom 56%om 56% • RecorRecord sales:d sales: Sales of NOK 51.1 million (41.8), up 22% reported and 30% currency neutral organic growth, with a currency headwind of 3.2 million. YTD sales of NOK 144.8 million (129.9), up 11% (17% currency neutral organic growth). • GrGrowth drivowth drivers:ers: fCAL turbo sales up 23% in Q3 (22% YTD) through BÜHLM ANN. US sales up 23% in Q3 (49% YTD), driven by Cystatin C. Asia down -33% YTD due to pricing and testing restrictions in China. • ImprImproovved pred profitabilityofitability:: EBITDA of NOK 13.6 million (8.4), an EBITDA margin of 27% (20%). Gross margin of 61% (56%), driven by higher production yields and a favourable geographic sales mix. YTD EBITDA of NOK 26.7 million (24.1) and gross margin of 56% (55%). • Non-rNon-recurring items:ecurring items: Q3 2026 operating profit is not affected by non-recurring items. YTD results include a non-cash impairment of NOK 30.2 million in Q1 related to the discontinued NT-proBNP project (included in R&D expenses, excluded from EBITDA). The underlying operating performance YTD improved compared with the same period last year when taking the impairment charge in Q1’26 into account. The reported YTD net result was NOK -8.5 million (9.8). • ComparabilityComparability:: All R&D costs are expensed in 2026, while NOK 1.3 million in Q3 2025 and NOK 5.5 million YTD 2025 were capitalised. The year-on-year improvement in profitability is therefore stronger than reflected in the reported EBITDA development. YTD sales include NOK 2.8 million in milestone-based development revenue (none in Q3). • Cash flowCash flow:: Operating cash flow of NOK 14.9 million (8.9) in Q3. YTD operating cash flow of NOK -0.9 million (16.5), mainly reflecting an increase in receivables of NOK 17.8 million. Cash of NOK 91.4 million at quarter end, after NOK 9.3 million in dividends paid in May. • Pipeline on track:Pipeline on track: The assay for a key IVD partner progressed from research to development and remains on track for launch in Q4 2027. Development work with Essange Reagents has started, and altogether seven assay and one technology development projects are active. ImprImprooving patient outcomes with world-ving patient outcomes with world- class diagnostics.class diagnostics. Q3Q3 | Gentian Diagnostics Third quarter 2026 results 3
Page 4
CEO Commentary – Record sales and significantly more new development projects initiated The third quarter of 2026 was another strong quarter for Gentian, with record sales of NOK 51.1 million, representing 22% reported growth and 30% currency-neutral organic gr owth compar ed to Q3 2025. The quar ter also deliv ered a significant improvement in profitability, with EBITDA increasing to NOK 13.6 million and gross margin improving to 61%. These results reflect both strong commercial execution and the scalability of our business model. Our key products continued to perform well. fCAL® turbo deliv ered excellent growth of 23% compared to the same quarter last year, driven by new account acquisitions and increasing testing volumes across regions. Overall, the BÜHLM ANN collaboration delivered strong results, and we expect the portfolio to continue growing above the company average in the coming quarters. Cystatin C also delivered nice growth, supported by recent investments, and increased partner activity in the United States. YTD, our sales in the US grew by 49% compared to 2025, further strengthening its position as one of Gentian's most important growth markets. Following the strategic review completed earlier this year, we continue to execute our updated R&D strategy with a clear focus on portfolio diversification, disciplined prioritisation and commercial relevance. During the quarter, we achieved several important development milestones. Our ongoing assay development project for a key IVD partner successfully transitioned from our Gothenburg research site to Moss. This transfer represents an important project milestone and brings the assay closer to the planned launch in 2027. Development activities with Essange Reagents have commenced as planned. Also, we continue to expand our opportunity pipeline through collaborations in veterinary diagnostics and high-sensitivity technology. More details will be shared as they become available, taking into account the competitive sensitivity of the information and any confidentiality obligations related to partner agreements. Together, these initiatives support a broader and clearly de-risked pipeline, with seven PETIA assay and one new technology platform projects up and running – a significant step change fr om only 6 months ago. We also continued to strengthen the clinical evidence base for GCAL®. New data pr esented at the European Paediatric Rheumatology Society Congress provided additional support for the clinical utility of serum calprotectin in juvenile idiopathic arthritis. While commercial adoption remains gradual, building strong clinical evidence remains a critical prerequisite for long-term market success. With record commercial performance, improving profitability and a pipeline that is progressing according to plan, Gentian enters the final quarter of 2026 with positive momentum. Our strategy remains unchanged: continue driving growth from our established portfolio while building a diversified pipeline of future products and technologies capable of delivering sustainable long-term value creation. Matti Heinonen, CEOMatti Heinonen, CEO, Gentian Diagnostics, Gentian Diagnostics Q3Q3 | Gentian Diagnostics Third quarter 2026 results 4
Page 5
About Gentian Diagnostics Gentian Diagnostics (OSE: GENT) develops and manufactures high-quality in vitro diagnostic reagents. Our mission is to improve diagnostic efficiency to support better treatment decisions. Gentian’s expertise and focus lie in immunoassays, specifically within infections, inflammation, and kidney disease. By converting existing, clinically relevant biomarkers to the most efficient high throughput analysers, the company contributes to cost savings and helps protect lives. Gentian Diagnostics is headquartered in Moss, Norway, and serves the global human and veterinary diagnostics markets through sales and representative offices in Sweden, the USA, and China. For more information, please visit www.gentian.com. Illustration of product categories Gentian’s strategy for long-term growth and value creation Gentian Diagnostics purpose is to deliver efficient diagnostics for better treatment decisions. The growing diagnostics market puts increasing pressure on clinical laboratory efficiency. However, many of the existing, clinically relevant biomarkers are available only on slow and inefficient platforms. Gentian’s solution is to utilise PETIA (particle-enhanced turbidimetric immunoassay), based on proprietary nanoparticle technology and knowhow, to convert existing biomarkers to the most efficient automated, high-throughput analysers. Gentian’s portfolio of high-impact diagnostic tests targets several large and growing disease areas such as infections and inflammation and kidney disease. The company has four established products – Cystatin C, fCAL ® turbo, canine CRP (cCRP) and fPELA® turbo – that contributed to 23% annual r evenue growth in 2020-2025. In addition, GCAL® has been launched and is in market development. The company has also undisclosed projects in exploration and optimisation phases. Q3Q3 | Gentian Diagnostics Third quarter 2026 results 5
Page 6
The company’s roadmap for long-term growth and value creation is founded on six strategic pillars: Grow annual revenue from the company’s established products by expanding market access through additional commercial partners and regulatory approvals. Prove clinical relevance of GCAL®. Bring a steady stream of new high-impact diagnostic tests to market. Secure one new contract with a global commercial partner every year, building on already established partnerships with major diagnostic companies across products. Stabilise the gross margin in the 55% to 60% range through economies of scale. Deliver long-term EBITDA margins of 40% through operational leverage and cost discipline, assuming that current investment levels are maintained. Q3Q3 | Gentian Diagnostics Third quarter 2026 results 6
Page 7
Operational summary Sales In the third quarter of 2026, Gentian once again delivered record quarterly sales of NOK 51.1 million, an increase of 22% from NOK 41.8 million in Q3 2025, corresponding to 30% currency-neutral organic growth. Sales for the first nine months of 2026 reached NOK 144.8 million, up 11% from the same period last year, equivalent to 17% currency-neutral organic growth. Cystatin CCystatin C Cystatin C sales in Q3 2026 were NOK 18.5 million, compared with NOK 15.5 million in Q3 2025, representing growth of 19%. For the first nine months of 2026, sales totalled NOK 50.2 million, compared with NOK 50.6 million in the corresponding period of 2025. The record-high quarterly sales were primarily driven by increasing demand from our largest partner in the United States, where awareness and adoption of Cystatin C testing continue to grow. Sales in China increased by 6% compared with Q3 2025, while other channels remained broadly in line with the prior-year quarter. Based on strong order intake for Q4, we expect Cystatin C to deliver year-over-year growth for the full year 2026. fCAL turbofCAL turbo fCAL turbo sales increased by 23% in Q3 2026 to NOK 19.5 million, compared with NOK 15.9 million in Q3 2025. Year-to- date sales reached NOK 53.1 million, up 22% from NOK 43.5 million in the same period last year. Growth was driven by successful acquisition of new accounts and increasing testing volumes across all regions. In addition, global partners continued to deliver according to expectations. fCAL turbo is exclusively commercialised by our partner BÜHLM ANN Laboratories. Other PrOther Productsoducts The Other Products category, consisting of fPELA turbo, GCAL, cCRP and milestone payments related to product developments, delivered mixed performance across the portfolio. Sales increased by NOK 0.2 million in Q3 2026 compared with Q3 2025. Cumulative sales for the first nine months of 2026 amounted to NOK 24.8 million, compared with NOK 21.0 million in the corresponding period of 2025, representing growth of 18%. A notable development was the continued uptake of fPELA testing among existing fCAL customers, reflecting the benefits of measuring both biomarkers from the same patient sample and collection device. ThirThird Pd Pararty Prty Productsoducts Sales in Gentian Diagnostics AB (GAB), the Company's Swedish distribution subsidiary reported under Third Party Products, increased by 72% to NOK 5.8 million in Q3 2026, compared with NOK 3.4 million in Q3 2025. Year-to-date sales amounted to NOK 16.6 million, compared with NOK 14.9 million in the same period last year, representing growth of 12% and reflecting continued solid demand in the Nordic market. Q3Q3 | Operational summary Third quarter 2026 results 7
Page 8
Regional PRegional Pererformanceformance The United States delivered solid regional performance in Q3 2026, with sales increasing 23% compared with Q3 2025. Year-to-date sales reached NOK 32.3 million, up 49% from NOK 21.7 million in the corresponding period last year. Demand for Cystatin C continued to increase, supported by broader clinical adoption, updated guidelines, and a growing body of scientific evidence. Growth was driven by both partner-led sales and direct customer activities. Sales in Europe reached NOK 33.3 million in Q3 2026, representing good growth of 24% compared with Q3 2025. For the first nine months of 2026, sales totalled NOK 96.4 million, an increase of 15% from the same period last year. Growth was primarily driven by continued strong performance of products commercialised through our partner BÜHLM ANN Laboratories. Sales in Asia increased by 6% in Q3 2026 to NOK 4.5 million compared with Q3 2025. For the first nine months of 2026, sales amounted to NOK 16.1 million, a decrease of 33% compared with the corresponding period of 2025. The decline continued to be driven by China, where government-imposed pricing and testing restrictions have impacted market demand. Continued growth in South Korea partially offset the lower sales recorded in China. Q3Q3 | Operational summary Third quarter 2026 results 8
Page 9
Market development GCAL® Gentian continues to expand the clinical positioning of GCAL across inflammatory, cardiovascular and infectious diseases, supporting earlier diagnosis, disease monitoring and treatment decisions. Commercial activities remain focused on increasing the adoption of serum/plasma calprotectin testing in inflammatory rheumatic diseases, in line with the strategic priorities of Gentian's commercial partners. StrStrengthening the clinical eengthening the clinical evidence base in paediatric rheumatologyvidence base in paediatric rheumatology New data presented at the European Paediatric Rheumatology Society (PReS) Congress in September further supported the clinical utility of serum calprotectin in juvenile idiopathic arthritis (JIA). Results from Gentian's prospective international JIJIA-COMPA-COMPASSASS study included 323 patient visits from 128 patients with non-systemic JIA and demonstrated that GCAL levels closely tracked disease activity. Consistent with expectations, GCAL concentrations were lower in patients in remission than in those with active disease and showed correlation with established clinical measures of disease activity. Patient follow-up is ongoing to further evaluate the potential of GCAL for monitoring treatment response and predicting disease flare. In addition, independent studies presented at PReS reported similar findings, providing further evidence that serum calprotectin reflects disease activity and may offer clinically relevant information beyond conventional inflammatory markers. Collectively, these data reinforce the growing body of evidence supporting the use of GCAL in disease monitoring and treatment decision-making in paediatric rheumatology. Q3Q3 | Operational summary Third quarter 2026 results 9
Page 10
Pipeline development R&D strategy execution During Q3, Gentian continued to execute the updated R&D strategy introduced in the previous quarter, with increased focus on portfolio diversification, accelerated development and disciplined prioritisation through strengthened pipeline governance process. The updated strategy is delivering a broader and more diversified development pipeline, with eight projects progressing in parallel through both strategic partnerships and internally initiated development activities. Accelerated prAccelerated product deoduct devvelopment and a brelopment and a broader pipeline.oader pipeline. Gentian is pursuing multiple PETIA development opportunities, combining projects initiated together with established and new IVD partners with internally identified opportunities addressing attractive clinical and market needs. This broader approach allows Gentian to leverage its existing technology platform and development capabilities while balancing development risk, commercial potential and time-to- market. In parallel, Gentian continues to explore opportunities to expand its assays onto turbidimetric point-of-care (POC) platforms through partnerships, targeting an attractive adjacent market and potentially extending the reach of the Company's assay portfolio beyond traditional core laboratory platforms. Opportunities within veterinary diagnostics also remain an important part of the pipeline. PParartnership-drivtnership-driven gren growth.owth. Business development and R&D are increasingly working together to identify and advance opportunities where Gentian's assay development capabilities can complement partners' diagnostic platforms and product portfolios. Several such opportunities are currently being evaluated or developed, supporting a more market- and customer-driven R&D pipeline. High-sensitivity technology (HST).High-sensitivity technology (HST). Development of Gentian's high-sensitivity technology continues as an important strategic initiative. The technology has the potential to significantly expand the range of biomarkers addressable by turbidimetric assays. Development activities are focusing on evaluating potential applications and partnership opportunities as well as generating data to further strengthen company’s unique IP around this technology. Overall, the Q3 pipeline reflects the intended direction of the updated strategy: a diversified portfolio of partner-driven and internally initiated projects, stronger market alignment, and parallel development activities aimed at increasing the pace and probability of successful product launches. Q3Q3 | Operational summary Third quarter 2026 results 10
Page 11
Ongoing and new pipeline projects Gentian continues to advance a broader and more balanced pipeline comprising partner-driven development programs, internally initiated projects and new technology opportunities. The assay development program for a key IVD partner has successfully transitioned from Gentian's research site in Gothenburg to its development organization in Moss, where activities are progressing according to plan. Successful transfer represents an important project milestone and brings the assay closer to the next phase of development. The project remains on track for the planned launch in Q4 2027. Following the partnership with Essange Reagents announced in June, development activities have been initiated and are progressing as planned. The collaboration is currently focused on four complementary assays, combining Essange's expertise in specialty immunology reagents with Gentian's capabilities in adapting assays for automated clinical chemistry platforms. The parties will evaluate the broader commercial potential of the portfolio beyond the existing interest of a global IVD partner. Within veterinary diagnostics, Gentian has submitted proposals for two paid development projects to a major veterinary IVD company, including the potential for Gentian to serve as assay manufacturer. During Q3, progress was made towards establishing a new collaboration, although formal confirmation and contractual arrangements remain pending. The high-sensitivity technology collaboration continues to progress, with the first co-development project advancing to the research prototype development phase. The collaboration represents an important step in evaluating Gentian's technology on turbidimetric point-of-care platforms and supports the Company's strategy of expanding its technology and assay capabilities beyond traditional core laboratory systems. Commercial terms remain under discussion. In parallel, Gentian continues to advance its internally initiated pipeline. One project focuses on the development of a new PETIA assay targeting an undisclosed clinically relevant biomarker with the potential to complement the existing product portfolio. The opportunity addresses an area of unmet clinical need and attractive long-term commercial potential. A second project is an early-stage exploratory PETIA program focused on a biomarker for the assessment of liver disease, with the potential to provide additional clinical value when used alongside existing markers as part of a broader liver diagnostics panel. In addition, Gentian is progressing a product improvement project for an existing assay aimed at enhancing product performance, strengthening product quality and improving manufacturing cost efficiency. Q3Q3 | Operational summary Third quarter 2026 results 11
Page 12
Long-term outlook Gentian targets disease groups that represent a total addressable market of around USD 6.9 billion globally and an estimated growth rate of 5-10% annually over the next 3-5 years, according to leading market data provider Kalorama1 (2024, 2025). From a macro perspective, key growth drivers include a growing and ageing population contributing to an increase in chronic, non-communicable and infectious diseases globally. The specific segments targeted by Gentian’s products add up to a total serviceable market of USD 1.9 billion (2025), with an estimated annual growth rate in line with the addressable market. Gentian’s growth ambitions and revenue potential are set to be de-risked through several key milestones for the company’s product portfolio over the coming 12 months. The key milestones are: Established products • Targeting additional large and medium-sized commercial partners globally • Additional regulatory approvals, including IVDR, MDSAP and FDA to allow for commercial expansion Market development GCAL® • To strengthen the clinical evidence base for GCAL® as a critical pr erequisite for long-term market success. • Securing endorsements from key opinion leaders and inclusion in clinical guidelines. • Securing global commercial partnerships with phased regional rollout. Product and pipeline development • Progress in the undisclosed project through remaining development steps towards regulatory filing and commercialization by the exclusive partner in late 2027, pending regulatory timelines. 1 The Worldwide Market for IVD tests, 17th and 18th edition, September 2024, September 2025 Q3Q3 | Long-term outlook Third quarter 2026 results 12
Page 13
• Achieving proof-of-concept for several new pipeline projects. • Continue investigations of high sensitivity technology. • Gentian continues to strengthen its pipeline by aligning internal development and strategic collaborations with clear market demand and defined routes to commercialization. Q3Q3 | Long-term outlook Third quarter 2026 results 13
Page 14
Financial performance Comparative numbers for Gentian in 2025 in (). Revenue, geographic split and product split Sales revenue increased by 22% to NOK 51.1 million in Q3 2026 (NOK 41.8 million), with currency neutral organic revenue growth of 30%. Year-to-date sales reached NOK 144.8 million (NOK 129.9 million), representing currency neutral organic revenue growth of 17% compared with the same period last year. Revenue from the US market was NOK 13.3 million for Q3 2026 (NOK 10.8 million), up 23% compared to Q3 2025, while year-to-date revenue reached NOK 32.3 million (NOK 21.7 million). Europe recorded revenue growth of 24% in Q3 2026, reaching NOK 33.3 million (NOK 26.8 million), with year-to-date revenue of NOK 96.4 million (NOK 84.0 million). Sales to Asia amounted to NOK 4.5 million (NOK 4.2 million) in Q3 2026, an increase of 6% compared to Q3 2025, while year-to- date revenue was NOK 16.1 million (NOK 24.1 million). Geographic split NOK millionNOK million Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 US 13.3 10.8 32.3 21.7 29.4 Europe 33.3 26.8 96.4 84.0 114.2 Asia 4.5 4.2 16.1 24.1 32.9 Total 51.1 41.8 144.8 129.9 176.5 The sales of Cystatin C increased by 19% to NOK 18.5 million (NOK 15.5 million) in Q3 2026, while year-to-date sales were NOK 50.2 million (NOK 50.6 million). fCAL turbo sales increased by 23% to NOK 19.5 million (NOK 15.9 million) in the quarter, with year-to-date sales reaching NOK 53.1 million (NOK 43.5 million), remaining the strongest growth driver year-to-date with a growth of 22%. Sales of third-party products distributed by the Swedish subsidiary, Gentian Diagnostics AB (GAB), increased by 72% to NOK 5.8 million (NOK 3.4 million) in Q3 2026, while year-to-date sales amounted to NOK 16.6 million (NOK 14.9 million), up 12% compared to the same period last year. The sales of other products were NOK 7.2 million (NOK 7.0 million) in the quarter. For the first nine months of 2026, sales amounted to NOK 24.8 million (NOK 21.0 million) including NOK 2.8 million in development revenue from a project partner from Q1 2026. Product split NOK millionNOK million Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Cystatin C 18.5 15.5 50.2 50.6 67.0 fCAL turbo 19.5 15.9 53.1 43.5 60.6 Third party products 5.8 3.4 16.6 14.9 21.2 Other 7.2 7.0 24.8 21.0 27.7 Total 51.1 41.8 144.8 129.9 176.5 Approximately 83%83% (67%67%) of the sales revenue in the quarter came from long-term contracts with established customers. Q3Q3 | Financial performance Third quarter 2026 results 14
Page 15
Gross margin % . Q4 2024Q1 2025 Q2 Q3 Q4 Q1 2026 Q2 Q3 40% 45% 50% 55% 60% 65% Sales Revenues (MNOK) Q4 2024Q1 2025 Q2 Q3 Q4 Q1 2026 Q2 Q3 0 10 20 30 40 50 Gross margin Gross margin in Q3 2026 was 61% (56%) of sales revenue. Gross margin YTD 2026 was 56% (55%). The gross margin for the quarter was positively influenced by above average operational performance which has resulted in higher production yields. A favourable geographical sales mix has also contributed to the improved gross margin. Gentian maintains its ambition that over time, the gross margin should be in the 55%-60% range. Operating expenses Net operating expenses, excluding cost of goods sold, amounted to NOK 21.8 million (NOK 18.4 million) in Q3 2026 and NOK 95.3 million (NOK 56.7 million) for the first nine months of 2026, including an impairment related to NT-proBNP of NOK 30.2 million recognised in Q1 2026. The impairment reflects the discontinuation of the NT-proBNP project following a strategic portfolio review, including updated information indicating that the project is no longer considered technologically feasible. The impairment is a non-cash accounting charge and does not impact on the company’s cash position. It should be viewed in the context of the company’s active portfolio management and ongoing prioritisation of development resources. R&D expenses amounted to NOK 8.4 million (NOK 6.1 million) in Q3 2026 and NOK 56.0 million (NOK 17.8 million) YTD 2026. R&D expenses are related to both technical and clinical data generation for our existing products and pipeline development of new products. In Q3 2026 expenses for technical and clinical support amounted to NOK 2.5 million (NOK 2.9 million) while NOK 5.9 million (NOK 4.5 million) was related to pipeline development. No amounts (NOK 1.3 million) were capitalised in the quarter. For the first nine months of 2026, technical and clinical support expenses amounted to NOK 7.1 million (NOK 7.3 million), and NOK 48.9 million (NOK 16.0 million) was related to pipeline development and the impairment of NT-proBNP. No amounts were capitalised year-to-date (NOK 5.5 million). Q3Q3 | Financial performance Third quarter 2026 results 15
Page 16
Earnings Operating profit before depreciation and amortization (EBITDA) ended at NOK 13.6 million (NOK 8.4 million) in Q3 2026 and NOK 26.7 million (NOK 24.1 million) year-to-date. Net profit was NOK 7.3 million (NOK 4.0 million) for the quarter and a net loss of NOK -8.5 million (net profit NOK 9.8 million) for the first nine months. Balance sheet Cash and cash equivalents as of 30 September 2026 were NOK 91.4 million (NOK 86.6 million). The cash is placed in both savings accounts and current accounts. The Company paid NOK 9.3 million (NOK 6.2 million) in dividends in May. Trade receivables as of 30 September 2026 were NOK 31.6 million (NOK 18.0 million), and inventory NOK 52.5 million (NOK 52.4 million). The equity ratio was 81.4% as of 30 September 2026. Events after the balance sheet date There are no events after the balance sheet date. Q3Q3 | Financial performance Third quarter 2026 results 16
Page 17
Statement of Profit and Loss – Gentian Diagnostics Group (unaudited) Note 20262026 20252025 20262026 20252025 20252025 (Amounts in NOK 1000) Q3 Q3 01.01-30.09 01.01-30.09 01.01-31.12 Sales revenues 3 51 070 41 835 144 759 129 907 176 499 Cost of goods sold 4,7 -20 079 -18 394 -63 152 -58 746 -78 300 GrGross pross profitofit 3030 991991 2323 441441 8181 607607 7171 161161 9898 199199 Other income 5,6 2 191 1 055 3 398 2 829 4 750 R&D expenses 7,8 -8 371 -6 057 -56 012 -17 836 -23 164 Sales and marketing expenses 7 -7 620 -7 274 -21 632 -20 713 -29 042 Administrative expenses 7 -5 816 -5 033 -17 606 -18 139 -25 292 Operating prOperating profitofit 1111 375375 66 133133 -10-10 246246 1717 302302 2525 452452 Finance income -119 1 450 3 772 3 103 5 431 Finance cost -1 735 -1 301 -4 955 -4 390 -5 216 Net financial itemsNet financial items -1-1 853853 149149 -1-1 183183 -1-1 287287 214214 PrProfit (loss) beforofit (loss) before taxe tax 99 521521 66 282282 -11-11 429429 1616 015015 2525 666666 Tax expense -2 176 -2 284 2 902 -6 226 -12 410 Net prNet profit (loss)ofit (loss) 77 346346 33 998998 -8-8 527527 99 788788 1313 256256 Other comprOther comprehensivehensive incomee income Items that will or may be reclassified to profit or loss: Exchange differences 605 107 539 1 271 507 TTotal other comprotal other comprehensivehensive incomee income 605605 107107 539539 11 271271 507507 TTotal comprotal comprehensivehensive income for the periode income for the period 77 951951 44 105105 -7-7 988988 1111 059059 1313 763763 Earnings per sharEarnings per sharee Basic EPS from net profit/(loss) 12 0.48 0.26 -0.55 0.63 0.86 Diluted EPS from net profit/(loss) 12 0.48 0.26 -0.55 0.63 0.86 Q3Q3 | Financial performance Third quarter 2026 results 17
Page 18
Statement of Financial Position – Gentian Diagnostics Group (unaudited) Note 20262026 20252025 20252025 (Amounts in NOK 1000) 30.09.30.09. 30.09.30.09. 31.12.31.12. AssetsAssets Non-currNon-current assetsent assets Intangible assets 9 4 005 32 293 35 833 Property, plant and equipment 4 454 4 358 4 417 Right-of-use assets 18 878 5 024 21 129 Deferred tax assets 14 15 721 19 003 12 819 TTotal non-currotal non-current assetsent assets 4343 058058 6060 678678 7474 198198 CurrCurrent assetsent assets Inventory 52 484 52 412 54 142 Accounts receivables and other receivables 47 434 32 959 24 270 Cash and cash equivalents 91 382 86 632 105 929 TTotal currotal current assetsent assets 191191 300300 172172 003003 184184 341341 TTotal assetsotal assets 234234 358358 232232 681681 258258 539539 EEquity and liabilitiesquity and liabilities PPaid-in equityaid-in equity Share capital 11 1 546 1 542 1 542 Share premium 294 988 293 810 293 810 Other paid-in equity 26 206 23 987 24 221 TTotal paid-in equityotal paid-in equity 322322 740740 319319 339339 319319 573573 Retained earningsRetained earnings Retained earnings -131 879 -117 320 -114 616 TTotal rotal retained equityetained equity -131-131 879879 -117-117 320320 -114-114 616616 TTotal equityotal equity 190190 861861 202202 019019 204204 957957 LiabilitiesLiabilities Lease liabilities 10 15 921 1 912 19 442 TTotal non-currotal non-current liabilitiesent liabilities 1515 921921 11 912912 1919 442442 CurrCurrent liabilitiesent liabilities Accounts payable and other current liabilities 27 575 28 750 34 140 TTotal currotal current liabilitiesent liabilities 2727 575575 2828 750750 3434 140140 TTotal liabilitiesotal liabilities 4343 496496 3030 662662 5353 582582 TTotal equity and liabilitiesotal equity and liabilities 234234 358358 232232 681681 258258 539539 Q3Q3 | Financial performance Third quarter 2026 results 18
Page 19
Statement of changes in equity (unaudited) SharShare capitale capital SharShare pre premiumemium Other paid-in capitalOther paid-in capital Retained earningsRetained earnings TTranslation diffranslation differerencesences TTotal equityotal equity (Amounts in NOK 1000) EEquity at 01.01.2026quity at 01.01.2026 11 542542 293293 810810 2424 221221 -114-114 233233 -383-383 204204 957957 Net result for the year -8 527 -8 527 Dividend -9 275 -9 275 Share-based payments (option programme) 1 690 1 690 Share-based payments (ESPP) 295 295 Issue of shares under ESPP 4 1 178 1 182 Other comprehensive income 539 539 EEquity at 30.09.2026quity at 30.09.2026 11 546546 294294 988988 2626 206206 -132-132 036036 157157 190190 861861 SharShare capitale capital SharShare pre premiumemium Other paid-in capitalOther paid-in capital Retained earningsRetained earnings TTranslation diffranslation differerencesences TTotal equityotal equity (Amounts in NOK 1000) EEquity at 01.01.2025quity at 01.01.2025 11 542542 293293 810810 2020 907907 -121-121 321321 -890-890 194194 050050 Net result for the year 9 788 9 788 Dividend -6 169 -6 169 Share-based payments (option programme) 3 079 3 079 Other comprehensive income 1 271 1 271 EEquity at 30.09.2025quity at 30.09.2025 11 542542 293293 810810 2323 987987 -117-117 701701 381381 202202 019019 SharShare capitale capital SharShare pre premiumemium Other paid-in capitalOther paid-in capital Retained earningsRetained earnings TTranslation diffranslation differerencesences TTotal equityotal equity (Amounts in NOK 1000) EEquity at 01.01.2025quity at 01.01.2025 11 542542 293293 810810 2020 907907 -121-121 321321 -890-890 194194 050050 Net result for the year 13 256 13 256 Dividend -6 169 -6 169 Share-based payments (option programme) 3 313 3 313 Other comprehensive income 507 507 EEquity at 31.12.2025quity at 31.12.2025 11 542542 293293 810810 2424 221221 -114-114 233233 -383-383 204204 957957 Q3Q3 | Financial performance Third quarter 2026 results 19
Page 20
Cash Flow Statement (unaudited) 20262026 20252025 20262026 20252025 20252025 (Amounts in NOK 1000) Q3 Q3 01.01-30.09 01.01-30.09 01.01-31.12 Operating activitiesOperating activities Profit (loss) before tax 9 521 6 282 -11 429 16 015 25 666 Depreciation and amortisation 2 235 2 245 6 693 6 774 9 115 Impairment - - 30 242 - - Change inventory 1 008 -758 1 659 -6 469 -8 200 Change accounts receivables -36 6 394 -17 794 5 264 9 501 Change accounts payables 2 000 -1 733 4 418 -1 144 -4 094 Share-based payments (option programme) 213 459 1 690 3 079 3 313 Share-based payments (ESPP) - - 295 - - Change in other assets and liabilities -84 -3 951 -16 709 -7 060 7 288 Net cash flow frNet cash flow from operating activitiesom operating activities 1414 857857 88 938938 -933-933 1616 459459 4242 590590 InvInvesting activitiesesting activities Payments of property, plant and equipment -2 175 -84 -2 266 -375 -1 207 Investment in intangible assets - -1 318 - -5 483 -9 552 Net cash flow frNet cash flow from invom investing activitiesesting activities -2-2 175175 -1-1 402402 -2-2 266266 -5-5 858858 -10-10 759759 Financing activitiesFinancing activities Lease payments -1 253 -1 260 -3 813 -3 797 -4 962 Dividends paid - - -9 275 -6 169 -6 169 Issue of shares under ESPP - - 1 182 - - Net cash flow frNet cash flow from financing activitiesom financing activities -1-1 253253 -1-1 260260 -11-11 906906 -9-9 966966 -11-11 131131 Net change in cash and cash equivNet change in cash and cash equivalentalent 11 430 6 276 -15 105 635 20 700 Cash and cash equivalents at beginning of period 79 341 80 249 105 929 84 738 84 738 Effect of currency translation of cash and cash equivalents 612 107 558 1 259 491 Net Cash and cash equivNet Cash and cash equivalents at period endalents at period end 9191 382382 8686 632632 9191 382382 8686 632632 105105 929929 Q3Q3 | Financial performance Third quarter 2026 results 20
Page 21
Notes Note 1. General information Gentian Diagnostics ASA is registered in Norway and listed on the Euronext Oslo Børs. The company 's headquarters are located at Bjørnåsv eien 5, 1596 Moss, Norway. Gentian is a research and development-based company that develops and manufactures biochemical reagents for use in medical diagnostics and research. The customers are medical laboratories and universities worldwide. The group consists of the parent company Gentian Diagnostics ASA and the subsidiary Gentian AS, also located in Norway. In addition, Gentian AS has a wholly owned subsidiary, registered in Florida, USA, named Gentian USA Inc., and a wholly owned subsidiary in Sweden, Gentian Diagnostics AB. Gentian Diagnostics AB also has a wholly owned subsidiary in Sweden, Getica AB. Amounts are in thousand Norwegian kroner unless stated otherwise. Note 2. Accounting principles The accounting policies applied in the preparation of the consolidated interim financial statements are consistent with those applied in the preparation of the annual IFRS financial statements for the year ended 31 December 2025. The group’s presentation currency is NOK (Norwegian kroner). This is also the parent company’s functional currency. The company uses currency rates published by the central bank of Norway (Norges Bank). 2.1 Basis of preparation The interim financial statements of the group have been prepared in accordance with IAS 34 Interim Financial Reporting. IFRS 18 "Presentation and Disclosure in Financial Statements", which will replace IAS 1 "Presentation of Financial Statements", becomes effective for annual reporting periods beginning on or after 1 January 2027. IFRS 18 introduces new requirements for presentation and disclosure in the financial statements. The group is currently assessing the impact of IFRS 18 and taking the necessary steps to prepare for its implementation. IFRS 18 is not expected to have a material impact on the recognition and measurement of the group's assets, liabilities, income or expenses. However, the standard is expected to result in changes to the presentation and disclosure in the financial statements. No other new accounting standards or interpretations issued, but not yet effective, are expected to have a material impact on the group’s financial statements in 2026. 2.2 Basis of consolidation The interim financial statements comprise the financial statements of the company and its subsidiaries. As of 30 September 2026, Gentian AS, located in Moss, Norway, is a 100% owned and controlled subsidiary. Q3Q3 | Notes Third quarter 2026 results 21
Page 22
Note 3. Sales revenue Sales rSales reevvenue Geographical splitenue Geographical split Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 Europe 33 336 26 814 96 353 84 049 114 183 Asia 4 474 4 239 16 088 24 124 32 879 USA 13 260 10 783 32 317 21 735 29 437 TTotalotal 5151 070070 4141 835835 144144 759759 129129 907907 176176 499499 Sales rSales reevvenue benue by pry product categoroduct categoryy Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 Renal diagnostic products 18 505 15 526 50 159 50 588 66 960 Inflammation diagnostic products 23 121 19 782 64 636 53 909 74 189 Other diagnostic products 9 444 6 528 27 156 25 410 35 350 Development revenue - - 2 808 - - TTotalotal 5151 070070 4141 835835 144144 759759 129129 907907 176176 499499 Note 4. Cost of goods sold Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 Change in inventory 1 008 -758 1 659 -6 469 -8 200 Purchase of raw materials and other components 7 913 9 720 27 958 33 994 44 848 Other manufacturing expenses 11 158 9 432 33 534 31 222 41 652 TTotalotal 2020 079079 1818 394394 6363 152152 5858 746746 7878 300300 Note 5. Other income Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 Public grants 2 191 1 055 3 398 2 829 4 750 Other income - - - - - TTotalotal 22 191191 11 055055 33 398398 22 829829 44 750750 Note 6. Public grants In some cases, Gentian is eligible for tax deductions under the Norwegian SkatteFUNN scheme related to research and development activities. In addition, the company may from time to time receive other grants from national and international programs. SkatteFUNN is recognised in accordance with IAS 20 as a government grant. Grants related to capitalised development projects are recognised as a reduction of capitalised development costs, while grants related to other projects are recognised in profit or loss as other income. Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 SkatteFUNN recognised in profit or loss 2 191 1 055 3 398 2 829 4 750 TTotalotal 22 191191 11 055055 33 398398 22 829829 44 750750 Q3Q3 | Notes Third quarter 2026 results 22
Page 23
Note 7. Expenses by nature Amounts in NOK 1000 Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Cost of materials 8 921 8 962 29 617 27 524 36 648 Employee benefit expenses 23 584 20 803 68 379 61 128 82 584 Depreciation 2 235 2 245 6 693 6 774 9 115 Impairment - - 30 242 - - Operating expenses in production 2 041 861 6 722 6 371 8 447 Other operating expenses 5 104 3 886 16 749 13 637 19 004 TTotalotal 4141 886886 3636 757757 158158 402402 115115 435435 155155 798798 Note 8. Research and Development (R&D) expenses Costs related to R&D projects consist of salary, external procurement of services, and other operating expenses. Development costs are capitalised when the recognition criteria in IAS 38 are met. The R&D department is also responsible for application validation. Recognised rRecognised researesearch and dech and devvelopment expenseselopment expenses Amounts in NOK 1000 Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Purchase of external services 333 350 1 763 1 787 3 046 Salary and other operating expenses 7 073 6 008 21 116 18 443 25 562 Depreciation and amortisation 965 1 016 2 891 3 090 4 109 Impairment - - 30 242 - - Capitalised research and development expenses - -1 318 - -5 483 -9 552 TTotalotal 88 371371 66 057057 5656 012012 1717 836836 2323 164164 Note 9. Intangible assets As of 30 September 2026, the recognised intangible assets in the group amounts to NOK 4 million and relate to capitalised development costs for diagnostic products. Development costs are capitalised when the criteria in IAS 38 are met, including demonstration of technological feasibility and probable future economic benefits. Intangible assets are tested for impairment at least annually, or when indications of impairment are identified, in accordance with IAS 36. The impairment test is performed at product level, representing the lowest level at which independent cash inflows can be identified. The recoverable amount is determined based on value in use using discounted cash flow models. The valuation involves significant estimates and assumptions, including expected future cash flows and discount rates, and is subject to uncertainty. During the first quarter of 2026, an impairment of NOK 30.2 million was recognised following the decision to discontinue the NT-proBNP project. As a result, the related capitalised development costs were fully impaired. The impairment is included in R&D expenses in the Statement of Profit or Loss. No further impairment losses were recognised as of 30 September 2026. Q3Q3 | Notes Third quarter 2026 results 23
Page 24
Note 10. Interest bearing debt Loan and related loan expenses is recorded in the balance sheet and expensed in the Statement of Profit and Loss at amortised cost. If a loan and loan expenses is related to an asset, and the real value of the asset is lower, the asset is written down to its real value. There was no value adjustment of assets in the first nine months of 2026. Gentian’s interest-bearing debt relates to equipment leases and lease liabilities recognised under IFRS 16. Note 11. Share capital and number of shares 20 largest shareholders in Gentian Diagnostics ASA as of 30 September 2026 according to VPS and disclosures from investors: Shareholder No of shares % DNB Bank ASA 2 110 224 13.65 % Kvantia AS 1 803 368 11.67 % Carpe Diem Afseth AS 1 000 000 6.47 % Norda ASA 716 099 4.63 % Safrino AS 649 700 4.20 % DNB Carnegie Investment Bank AB 645 621 4.18 % Insr ASA 614 251 3.97 % J.P. Morgan SE 600 000 3.88 % DNB Bank ASA, Meglerkonto Innland 571 169 3.69 % Verdipapirfondet Delphi Norge 389 572 2.52 % Intertrade Shipping AS 360 000 2.33 % Krefting, Johan Henrik 325 100 2.10 % Verdipapirfondet DNB Smb 304 097 1.97 % Alfaplan AS 303 000 1.96 % Manheim, Joachim Fasting 237 939 1.54 % Lioness AS 220 000 1.42 % Marstal AS 212 407 1.37 % T.D. Veen AS 195 000 1.26 % Skandinaviska Enskilda Banken AB 180 000 1.16 % Caaby AS 173 500 1.12 % Other Shareholders 3 847 577 24.89 % Total shares 15 458 624 100% Q3Q3 | Notes Third quarter 2026 results 24
Page 25
Note 12. Earnings per share Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Earnings/ loss (-) for the period 7 345 598 3 997 830 -8 527 388 9 788 177 13 256 160 Number of sharNumber of shares:es: Weighted average number of outstanding ordinary shares 15 458 624 15 422 350 15 443 609 15 422 350 15 422 350 EEffffect of dilutivect of dilutive potential share potential shares:es: Share options - 91 959 - 49 273 66 582 Weighted average number of shares issued with diluted effect 15 458 624 15 514 309 15 443 609 15 471 623 15 488 932 Basic earnings/ loss (-) per share 0.48 0.26 -0.55 0.63 0.86 Diluted earnings/loss (-) per share 0.48 0.26 -0.55 0.63 0.86 Note 13. Share-based compensation SharShare option pre option programogram The company has a share option program covering certain key personnel. Per 30 September 2026, the program has fourteen members. The share option program for key personnel is settled in shares, however, the company may resolve settlement in cash. The fair value of the issued options is expensed over the vesting period: For options issued from 2021,1/3 of the options will vest 24 months after the day of grant, 1/3 will vest 36 months after the day of grant and 1/3 will vest 48 months. For options issued from 2022, 2023 and 2024, 1/2 of the options will vest after 36 months and 1/2 of the options will vest after 48 months. Unvested options may be cancelled if the holder terminates its employment with the group. The cost of the employee share-based transaction is expensed over the average vesting period. The value of the issued options of the transactions that are settled with equity instruments (settled with the company’s own shares) is recognised as salary and personnel cost in profit and loss and in other paid-in capital. The value of the issued options of the programs that are settled in cash (cash-based programs) is recognised as salary and personnel cost in profit and loss and as a liability in the balance sheet. The liability is measured at fair value at each balance sheet date until settlement, and changes in the fair value are recognised in profit and loss. Social security tax on options is recorded as a liability and is recognised over the estimated vesting period. Q3'26Q3'26 Q3'25Q3'25 20252025 Outstanding options at beginning of period 968 132 1 048 132 1 080 632 Options terminated -70 000 - -32 500 Options expired - - -80 000 Outstanding options at end of period 898 132 1 048 132 968 132 Q3Q3 | Notes Third quarter 2026 results 25
Page 26
The outstanding options are subject to the following conditions: ExpirExpiry datey date AAvverage strikerage strike pricee price Number of sharNumber of sharee optionsoptions 2026-11 72.60 113 174 2027-12 46.67 189 996 2028-11 40.17 309 962 2029-11 52.39 285 000 898 132 No share options were granted during the quarter. Note 14. Tax The group has recognised a deferred tax asset related to previously unutilized tax losses. The recognition is based on the profitability of the subsidiary Gentian AS and management’s assessment that sufficient taxable profits will be generated within the next five years to utilise these tax losses. The recognised deferred tax asset amounts to NOK 15.7 million and relates to tax losses carried forward in Gentian AS. The total loss carried forward for the group as of 30 September 2026 amounts to NOK 152.6 million. Q3Q3 | Notes Third quarter 2026 results 26
Page 27
Alternative performance measures Non‐IFRS financial measures / alternative performance measures In this quarterly report, the group presents certain alternative performance measures ("APMs"). An APM is defined as a financial measure of historical or future financial performance, financial position, or cash flows, other than a financial measure defined or specific in the applicable financial reporting framework (IFRS). The APMs presented herein are not measurements of financial performance or liquidity under IFRS or other generally accepted accounting principles, are not audited and investors should not consider any such measures to be an alternative to (a) operating revenues or operating profit (as determined in accordance with generally accepted accounting principles), (b) as a measure of the group's operating performance; or (c) any other measures of performance under generally accepted accounting principles. The APMs presented herein may not be indicative of the group's historical operating results, nor are such measures meant to be predictive of the group's future results. The company uses APMs to measure operating performance and is of the view that the APMs provide investors with relevant and specific operating figures which may enhance their understanding of the group's performance. Because companies calculate APMs differently, the APMs presented herein may not be comparable to similarly titled measures used by other companies. Below is an overview of APMs presented, including an overview of reconciliation and calculation of the relevant APMs. Currency neutral organic revenue growth Currency neutral organic revenue growth is defined as revenue adjusted for currency effects and effects from M&A. Currency neutral organic revenue growth measurement provides useful information to investors and other stakeholders on underlying growth of the business without the effect of certain factors unrelated to its operating performance. ReconciliationReconciliation Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 Sales revenues 51 070 41 835 144 759 129 907 176 499 Revenue growth 9 235 9 137 14 851 20 449 24 430 Impact using exchange rates from last period 3 190 883 7 786 -83 1 126 Impact M&A - - - - - Currency neutral organic revenue growth 12 425 10 019 22 637 20 367 25 557 Currency neutral organic revenue growth % 30% 31% 17% 19% 17% Q3Q3 | Notes Third quarter 2026 results 27
Page 28
EBITDA EBITDA is a measurement of operating earnings before depreciation and amortisation of tangible and intangible assets and impairment charges. EBITDA is used to provide information about operating performance and facilitate comparison with other companies. EBITDA Margin is defined as EBITDA as a percentage of sales revenues. ReconciliationReconciliation Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 Operating profit 11 375 6 133 -10 246 17 302 25 452 Depreciation and amortisation 2 235 2 245 6 693 6 774 9 115 Impairment - - 30 242 - - EBITDA 13 610 8 378 26 690 24 075 34 567 EBITDA Margin 27% 20% 18% 19% 20% Gross Margin Gross margin refers to gross profit in % of sales revenues. Gross Margin % is used to provide consistent information about production-related performance and facilitate comparison with other companies. Q3'26Q3'26 Q3'25Q3'25 YYTD Q3'26TD Q3'26 YYTD Q3'25TD Q3'25 20252025 Amounts in NOK 1000 Sales revenues 51 070 41 835 144 759 129 907 176 499 Cost of goods sold -20 079 -18 394 -63 152 -58 746 -78 300 Gross profit 30 991 23 441 81 607 71 161 98 199 Gross Margin 61% 56% 56% 55% 56% Equity ratio Equity ratio refers to equity in % of total equity and liabilities. 20262026 20252025 20252025 Amounts in NOK 1000 30.09 30.09 31.12 Total equity 190 861 202 019 204 957 Total equity and liabilities 234 358 232 681 258 539 Equity ratio 81.4 % 86.8 % 79.3 % Q3Q3 | Notes Third quarter 2026 results 28